Summary:

Antibody therapeutics are increasingly engineered for specific Fc-mediated effector functions, but optimizing for safety and efficacy is more complex than it appears. In this presentation from the 2024 Fc-Mediated Function Summit, Dr. Lenny Moise explores how SeromYx’s industrialized, high-throughput platform enables comprehensive profiling of Fc effector functions, revealing unexpected tradeoffs and guiding smarter therapeutic design. Learn why functional characterization must go beyond affinity and subclass to capture the real-world impact of engineered antibodies.

Key Highlights:

• Function doesn’t follow form: Engineering antibodies for enhanced or silenced Fc effector functions can unintentionally impact other functions, often unpredictably.
  
• One Fab, many outcomes: Antibodies with identical Fab or Fc regions can still exhibit widely different effector profiles depending on target epitope and context.
  
• Data that drives decisions: Early, multiplexed functional assessment across 15 Fc effector assays helps derisk lead candidate selection, streamline regulatory readiness, and ultimately improve clinical outcomes.